Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Adult
Aged
Antiviral Agents
/ therapeutic use
Betacoronavirus
/ isolation & purification
COVID-19
Coronavirus Infections
/ epidemiology
Disease Progression
Drug Combinations
Female
Humans
Lopinavir
/ adverse effects
Male
Middle Aged
Oxygen Inhalation Therapy
Pandemics
Pneumonia, Viral
/ epidemiology
Polymerase Chain Reaction
Respiratory Tract Infections
/ virology
Ritonavir
/ adverse effects
SARS-CoV-2
Singapore
/ epidemiology
Virus Shedding
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
pubmed:
4
3
2020
medline:
23
9
2020
entrez:
4
3
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China. To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management. Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020. Confirmed SARS-CoV-2 infection. Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool. Clinical course was summarized, including requirement for supplemental oxygen and intensive care and use of empirical treatment with lopinavir-ritonavir. Among the 18 hospitalized patients with PCR-confirmed SARS-CoV-2 infection (median age, 47 years; 9 [50%] women), clinical presentation was an upper respiratory tract infection in 12 (67%), and viral shedding from the nasopharynx was prolonged for 7 days or longer among 15 (83%). Six individuals (33%) required supplemental oxygen; of these, 2 required intensive care. There were no deaths. Virus was detectable in the stool (4/8 [50%]) and blood (1/12 [8%]) by PCR but not in urine. Five individuals requiring supplemental oxygen were treated with lopinavir-ritonavir. For 3 of the 5 patients, fever resolved and supplemental oxygen requirement was reduced within 3 days, whereas 2 deteriorated with progressive respiratory failure. Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results. Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection. Some patients required supplemental oxygen and had variable clinical outcomes following treatment with an antiretroviral agent.
Identifiants
pubmed: 32125362
pii: 2762688
doi: 10.1001/jama.2020.3204
pmc: PMC7054855
doi:
Substances chimiques
Antiviral Agents
0
Drug Combinations
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1488-1494Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care Med. 2020 Feb;48(2):e98-e106
pubmed: 31939808
N Engl J Med. 2016 Sep 29;375(13):1303-5
pubmed: 27682053
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Emerg Infect Dis. 2004 Sep;10(9):1550-7
pubmed: 15498155
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Hong Kong Med J. 2003 Dec;9(6):399-406
pubmed: 14660806
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
JAMA. 2020 Apr 7;323(13):1243-1244
pubmed: 32077901
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565